AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]

Summary

This study is a single arm, multi-center phase II study of AZD 2811 monotherapy in patients with relapsed small cell lung cancer (SCLC) as a second or third line therapy. Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.

Timeline

Start

2017-12-01

Primary completion

2018-10-08

Completion

2018-10-29

Outcome

Outcome not reported

Stopped: “Early detection of the purpose of the study.”

Drugs

Indications